Literature DB >> 10993150

C19 odd-chain polyunsaturated fatty acids (PUfas) are metabolized to C21-PUfas in a rat liver cell line, and curcumin, gallic acid, and their related compounds inhibit their desaturation.

N Nakano1, N Shirasaka, H Koyama, M Hino, T Murakami, S Shimizu, H Yoshizumi.   

Abstract

It was demonstrated that the rat liver cell line BRL-3A converted exogenous C19 odd chain-polyunsaturated fatty acids (PUFAs) into the corresponding C21- and C23-PUFAs as follows: 21:3n-8, 21:4n-8, 23:3n-8, and 23:4n-8 (from 19:3n-8); 21:4n-5, 21:5n-5, 23:4n-5, and 23:5n-5 (from 19:4n-5); 21:5n-2, 21:6n-2, 23:5n-2, and 23:6n-2 (from 19:5n-2). It presumed that these C19 PUFAs were converted through the mimic route to docosahexaenoic acid (22:6n-3) from eicosapentaenoic acid (20:5n-3). In addition, the characterization of the change of fatty acid composition of cellular lipids in rat liver cells were examined, using 19:4n-5 and several fatty acid desaturation inhibitors. Curcumin related compounds, curcumin, capsaicin, isoeugenol, 4-(4-hydroxy-3-methoxyphenyl)-3-buten-2-one, and gallic acid esters with near five carbon numbered alcohol had great changes of fatty acid composition of cellular lipids based on inhibition of the A6 desaturation of C24-PUFAs in rat liver cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10993150     DOI: 10.1271/bbb.64.1641

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  2 in total

1.  Comparative study of serine-plasmalogens in human retina and optic nerve: identification of atypical species with odd carbon chains.

Authors:  Kornél Nagy; Viral Vishnuprasad Brahmbhatt; Olivier Berdeaux; Lionel Bretillon; Frédéric Destaillats; Niyazi Acar
Journal:  J Lipid Res       Date:  2012-01-19       Impact factor: 5.922

2.  Gallic Acid Induces a Reactive Oxygen Species-Provoked c-Jun NH2-Terminal Kinase-Dependent Apoptosis in Lung Fibroblasts.

Authors:  Chiu-Yuan Chen; Kun-Chieh Chen; Tsung-Ying Yang; Hsiang-Chun Liu; Shih-Lan Hsu
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-20       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.